Péter L. Lakatos

33.3k total citations · 6 hit papers
481 papers, 14.3k citations indexed

About

Péter L. Lakatos is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Péter L. Lakatos has authored 481 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 304 papers in Genetics, 247 papers in Epidemiology and 134 papers in Surgery. Recurrent topics in Péter L. Lakatos's work include Inflammatory Bowel Disease (287 papers), Microscopic Colitis (211 papers) and Eosinophilic Esophagitis (46 papers). Péter L. Lakatos is often cited by papers focused on Inflammatory Bowel Disease (287 papers), Microscopic Colitis (211 papers) and Eosinophilic Esophagitis (46 papers). Péter L. Lakatos collaborates with scholars based in Hungary, Canada and United States. Péter L. Lakatos's co-authors include Johan Burisch, Tine Jess, Matteo Martinato, Stephan R. Vavricka, Mária Papp, Gerhard Rogler, Lóránt Gönczi, Talat Bessissow, Siew C. Ng and Edward V. Loftus and has published in prestigious journals such as The Lancet, Gastroenterology and PLoS ONE.

In The Last Decade

Péter L. Lakatos

450 papers receiving 14.0k citations

Hit Papers

The burden of inflammator... 2013 2026 2017 2021 2013 2015 2016 2013 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The burden of inflammatory bowel disease in Europe
    2013 730 citations Péter L. Lakatos et al. Journal of Crohn s and Colitis profile →
  2. Extraintestinal Manifestations of Inflammatory Bowel Disease
    2015 515 citations Stephan R. Vavricka, Alain Schoepfer et al. Inflammatory Bowel Diseases profile →
  3. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations
    2016 506 citations Gerhard Rogler, Péter L. Lakatos et al. Journal of Crohn s and Colitis profile →
  4. Geographical variability and environmental risk factors in inflammatory bowel disease
    2013 461 citations Péter L. Lakatos et al. profile →
  5. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
    2017 382 citations Péter L. Lakatos et al. profile →
  6. The Burden of Inflammatory Bowel Disease in Europe in 2020
    2021 265 citations Lóránt Gönczi, Péter L. Lakatos et al. Journal of Crohn s and Colitis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Péter L. Lakatos Hungary 58 8.4k 6.7k 4.1k 2.3k 1.9k 481 14.3k
Axel Dignaß Germany 55 10.1k 1.2× 7.1k 1.1× 5.1k 1.3× 2.7k 1.2× 2.3k 1.2× 282 17.3k
Jill M. Norris United States 70 5.4k 0.6× 2.9k 0.4× 4.1k 1.0× 1.8k 0.8× 1.9k 1.0× 313 16.8k
Paolo Pozzilli Italy 62 6.4k 0.8× 1.4k 0.2× 5.6k 1.4× 1.6k 0.7× 2.4k 1.2× 443 14.3k
William J. Tremaine United States 70 13.7k 1.6× 11.0k 1.6× 7.2k 1.8× 2.0k 0.9× 989 0.5× 268 19.3k
Anne M. Griffiths Canada 77 16.1k 1.9× 11.3k 1.7× 7.3k 1.8× 3.6k 1.5× 2.6k 1.3× 363 23.0k
Daniël W. Hommes Netherlands 58 5.5k 0.7× 3.7k 0.6× 2.9k 0.7× 2.9k 1.2× 2.8k 1.5× 217 12.6k
Sandro Ardizzone Italy 50 6.9k 0.8× 5.2k 0.8× 3.6k 0.9× 1.5k 0.6× 771 0.4× 236 10.7k
Jeffrey S. Hyams United States 61 8.9k 1.1× 6.3k 0.9× 5.3k 1.3× 2.4k 1.0× 997 0.5× 318 16.6k
Stephan R. Vavricka Switzerland 50 5.4k 0.6× 4.3k 0.6× 3.0k 0.7× 1.5k 0.7× 2.2k 1.1× 240 11.0k
Sunanda V. Kane United States 55 6.5k 0.8× 4.6k 0.7× 3.7k 0.9× 2.6k 1.1× 703 0.4× 304 11.4k

Countries citing papers authored by Péter L. Lakatos

Since Specialization
Citations

This map shows the geographic impact of Péter L. Lakatos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Péter L. Lakatos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Péter L. Lakatos more than expected).

Fields of papers citing papers by Péter L. Lakatos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Péter L. Lakatos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Péter L. Lakatos. The network helps show where Péter L. Lakatos may publish in the future.

Co-authorship network of co-authors of Péter L. Lakatos

This figure shows the co-authorship network connecting the top 25 collaborators of Péter L. Lakatos. A scholar is included among the top collaborators of Péter L. Lakatos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Péter L. Lakatos. Péter L. Lakatos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lakatos, Péter L., Victoria Marcus, Waqqas Afif, et al.. (2025). Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases. 31(11). 2977–2985.
2.
Afif, Waqqas, Alain Bitton, Gary Wild, et al.. (2024). P716 Efficacy and safety of upadacitinib during induction in Crohn’s disease: Real-world experience. Journal of Crohn s and Colitis. 18(Supplement_1). i1337–i1337. 1 indexed citations
3.
Tóth, Béla, et al.. (2024). Safety and Efficacy of Loading Doses of Vitamin D: Recommendations for Effective Repletion. Pharmaceuticals. 17(12). 1620–1620. 2 indexed citations
4.
Wetwittayakhlang, Panu, et al.. (2024). Efficacy of Vonoprazan vs. Intravenous Proton Pump Inhibitor in Prevention of Re-Bleeding of High-Risk Peptic Ulcers: A Randomized Controlled Pilot Study. Journal of Clinical Medicine. 13(12). 3606–3606. 1 indexed citations
5.
6.
Wetwittayakhlang, Panu, Christine Verdon, Michael Starr, et al.. (2023). Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study. The Turkish Journal of Gastroenterology. 34(6). 603–610. 1 indexed citations
7.
Kürti, Zsuzsanna, et al.. (2023). Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary. The Turkish Journal of Gastroenterology. 34(5). 508–515. 2 indexed citations
8.
Wetwittayakhlang, Panu, Waqqas Afif, Gary Wild, et al.. (2023). Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Digestive and Liver Disease. 56(1). 35–42. 10 indexed citations
9.
Wetwittayakhlang, Panu, et al.. (2023). Stable Incidence and Risk Factors of Colorectal Cancer in Ulcerative Colitis: A Population-Based Cohort Between 1977–2020. Clinical Gastroenterology and Hepatology. 22(1). 191–193.e3. 6 indexed citations
10.
11.
Restellini, Sophie, Alain Bitton, Gary Wild, et al.. (2023). Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases. Crohn s & Colitis 360. 5(1). otad004–otad004. 4 indexed citations
12.
Wetwittayakhlang, Panu, Lóránt Gönczi, Petra A. Golovics, et al.. (2023). Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020. Journal of Clinical Medicine. 12(8). 3026–3026. 5 indexed citations
13.
14.
Rencz, Fanni, Péter L. Lakatos, László Gulàcsi, et al.. (2018). Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease. Quality of Life Research. 28(1). 141–152. 45 indexed citations
15.
Fernandes, Samuel, Cilénia Baldaia, Paulo Moura, et al.. (2016). P484. Access to biologics and biosimilars across 11 European Union countries. Journal of Crohn s and Colitis. 10(suppl 1). S345.2–S345. 1 indexed citations
16.
Ďuricová, Dana, Mathurin Fumery, Vito Annese, et al.. (2016). The natural history of Crohn’s disease in children: a review of population-based studies. European Journal of Gastroenterology & Hepatology. 29(2). 125–134. 52 indexed citations
17.
Vavricka, Stephan R., Gerhard Rogler, Muriel Spoerri, et al.. (2015). Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflammatory Bowel Diseases. 21(8). 1794–1800. 188 indexed citations
18.
Müller, Katalin Eszter, Péter L. Lakatos, Mária Papp, & Gábor Veres. (2014). Incidence and Paris Classification of Pediatric Inflammatory Bowel Disease. Gastroenterology Research and Practice. 2014. 1–10. 38 indexed citations
19.
Póliska, Szilárd, András Penyige, Péter L. Lakatos, et al.. (2011). Association of peroxisome proliferator-activated receptor gamma polymorphisms with inflammatory bowel disease in a Hungarian cohort. Inflammatory Bowel Diseases. 18(3). 472–479. 13 indexed citations
20.
Lakatos, Péter L., Gábor Mester, Zsuzsanna Erdélyi, et al.. (2004). Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World Journal of Gastroenterology. 10(3). 404–404. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Axel Dignaß Breakdown of academic impact, for papers by Jill M. Norris Breakdown of academic impact, for papers by Paolo Pozzilli Breakdown of academic impact, for papers by William J. Tremaine Breakdown of academic impact, for papers by Anne M. Griffiths Breakdown of academic impact, for papers by Daniël W. Hommes Breakdown of academic impact, for papers by Sandro Ardizzone Breakdown of academic impact, for papers by Jeffrey S. Hyams Breakdown of academic impact, for papers by Stephan R. Vavricka Breakdown of academic impact, for papers by Sunanda V. Kane
Rankless by CCL
2026